Welcome to the e-CCO Library!

P524: Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn's disease.
Year: 2022
Source: ECCO'22
Authors: Riviere, P.(1);Kanters, C.(2);Ni, A.(2);Pellet, G.(1);Hupe, M.(1);Aboulhamid, N.(2);Poullenot, F.(1);Bitton, A.(2);Zerbib, F.(1);Lakatos, P.(2);Afif, W.(2);Laharie, D.(1);Bessissow, T.(2);
Created: Friday, 11 February 2022, 3:56 PM
P524: Endoscopic dilations of intestinal stenosis in Crohn's disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Badre, W.(1);Bahlaoui, O.(1);El Rhaoussi, F.Z.(1);Tahiri, M.(1);Haddad, F.(1);Hliwa, W.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P524: Long-term outcomes after restorative proctocolectomy and ileal pouch-anal anastomosis in children compared to adults
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Diederen K.*1, Sahami S.2, Tabbers M.1, Benninga M.1, Kindermann A.1, Tanis P.2, Oomen M.3, Bemelman W.2, de Jong J.3

Created: Wednesday, 20 February 2019, 10:36 AM
P524: Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schreiber, S.(1);Ben-Horin, S.(2);Ye, B.D.(3);Kim, D.H.(4);Reinisch, W.(5)*;
Created: Friday, 14 July 2023, 11:05 AM
P524: Systematic review of calcineurin inhibitors (CNI) and vedolizumab (VDZ) combination therapy in acute severe ulcerative colitis (ASUC)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Lin*1, W-C. Lim1

Created: Friday, 22 February 2019, 9:41 AM
P525 Rheumatoid arthritis treatment with filgotinib: Week 156 safety and efficacy data from a phase 2b open-label extension study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Besuyen1, A. Kavanaugh2, R. Westhovens3, K. Winthrop4, S. Lee5, J. Greer6, A. DeZure6, D. An7, L. Ye7, J. Sundy6, L. Meuleners8, R. Alten9, M. Genovese10

Created: Thursday, 30 January 2020, 10:12 AM
P525: A prospective interventional study to evaluate the effect of hypoxia on healthy volunteers and patients with inflammatory bowel disease: The altitude IBD study
Year: 2022
Source: ECCO'22
Authors: Vavricka, S.(1);Zeitz, J.(2);Madanchi, M.(1);Biedermann, L.(1);Morsy, Y.(1);Scharl, M.(1);Gassmann, M.(3);Lutz, T.(3);Kunz, A.(4);Bron, D.(4);Rogler, G.(1);Greuter, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P525: Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centre
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Null1*, H.L. Chang2, T. Lissoos1, M. Luo1, B. Cohen2, B.E. Sands2, A. Atreja2

Created: Thursday, 21 February 2019, 9:14 AM
P525: Effectiveness and safety of vedolizumab in IBD patients: a multicentre experience of “real world data” from the UK
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lenti M.V.*1, Levison S.2, Eliadou E.2, Willert R.2, Kemp K.2, Stansfield C.3, Assadsangabi A.3, Singh S.4, Crooks B.4, Tattersall S.4, Kenneth C.5, Subramanian S.6, Probert C.6, Smith P.7, Liu E.7, Limdi J.K.8, Hamlin P.J.1, Selinger C.P.1

Created: Wednesday, 20 February 2019, 10:36 AM
P525: Patients' Perception of Risks of biologic therapy During Covid-19 Pandemic in Israel Orly Lior, Ilia Sergeev, Nahum Ruhimovich, Michal Openheim, Fabiana Benjaminov, Dan Feldman, Yehuda Ringel, Timna Naftali Division of Gastroenterology and Liver Diseases, Meir Medical Center, Kfar Saba, Israel
Year: 2021
Source: ECCO'21 Virtual
Authors: Lior, O.(1);Sergeev, I.(1);Ruhimovich, N.(1);Openheim, M.(1);Benjaminov, F.(1);Feldman, D.(1);Ringel, Y.(1);Naftali, T.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P525: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: a systematic review and meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Taxonera, C.(1)*;Olivares, D.(1);Olga N, L.G.(2);Alba, C.(1);
Created: Friday, 14 July 2023, 11:05 AM
P525: The benefits of anti-TNF drug and antidrug antibody (ADAb) level monitoring in a DGH
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Matthews*1, I. London1, I. Reilly1, T. Maheswaren1, A. Lewis Williams1, S. Michail1

Created: Friday, 22 February 2019, 9:41 AM
P526 Body mass index and response to TNF-α inhibitors in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Nordin1, B. Shadbolt2, K. Subramaniam1,3

Created: Thursday, 30 January 2020, 10:12 AM
P526: A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Van Linschoten, R.(1,2)*;Jansen, F.(3);Pauwels, R.(2);Smits, L.(3);Atsma, F.(4);Kievit, W.(5);de Jong, D.(3);de Vries, A.(2);Boekema, P.(6);West, R.(1);Bodelier, A.(7);Gisbertz, I.(8);Wolfhagen, F.(9);Romkens, T.(10);Lutgens, M.(11);van Bodegraven, A.(12);Oldenburg, B.(13);Pierik, M.(14);Russel, M.(15);de Boer, N.(16);Mallant-Hent, R.(17);ter Borg, P.(18);van der Meulen-de Jong, A.(19);Jansen, J.(20);Jansen, S.(21);Tan, A.(22);van der Woude, C.J.(2);Hoentjen, F.(23);
Created: Friday, 14 July 2023, 11:05 AM
P526: A prospective 52-week mucosal healing and deep remission assessment of small bowel and colonic Crohn's disease as detected by colon capsule endoscopy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Oliva S.*1, Cohen S.2, Civitelli F.1, Aloi M.1, Viola F.1, Casciani E.3, Maccioni F.4, Hassan C.5, Papoff P.6, Cucchiara S.1

Created: Wednesday, 20 February 2019, 10:36 AM
P526: Early sonographic response predicts long-term outcome in Crohn’s disease: A prospective cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Novak1*, J. Halasz1, C. Lu1, G. Kaplan1,2, C. Seow1, D. Tanyingoh2, S. Devlin1, R. Panaccione1, S. Wilson3

Created: Thursday, 21 February 2019, 9:14 AM
P526: Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patients
Year: 2022
Source: ECCO'22
Authors: DebenMSc, D.(1);Van Moorsel, F.(2,3);Creemers, R.(4,5);Winkens, B.(6);Bus, P.(7);Pierik, M.(5);Simsek, M.(8);De Boer, N.(8);Wong, D.(1);Van Bodegraven, A.(4,8);
Created: Friday, 11 February 2022, 3:56 PM
P526: Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Alonso Abreu*1, O. Alarcón-Fernández1, M. Carrillo-Palau1, L. Ramos López1, J. P. Gisbert2, M. Chaparro2, P. Nos3, A. Jiménez Sosa4, E. Quintero Carrión1, GETECCU1

Created: Friday, 22 February 2019, 9:41 AM
P527 A review of adverse events associated with immunosuppressive treatments in inflammatory bowel disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Tassone1, N. Ding2

Created: Thursday, 30 January 2020, 10:12 AM